Compare Charles River Laboratories Intl. Inc (CRL) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Gemini Space Station Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Gemini Space Station Inc trades at $4.39 (market cap $548.72M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 20.3× Gemini Space Station Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| CRL | GEMI | |
|---|---|---|
Market Cap | $11.14B | $548.72M |
Sector | Health | Technology |
52-Week High | $233.60 | $32.52 |
52-Week Low | $145.57 | $3.91 |
Enterprise Value | $14.00B | $538.70M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
GEMI trades at $4.25, down 1.39% on the day, amid a bearish technical signal and weak fundamentals. The company reported significant losses, with a net income margin of -278.9% in 2025, and has missed earnings expectations for three consecutive quarters. Recent news includes a class action lawsuit and a $100 million investment from Winklevoss Capital, creating mixed sentiment.
The outlook remains challenging due to persistent unprofitability and legal risks, though analyst consensus suggests moderate upside with a $5.88 price target. Investment opportunity hinges on the company's ability to leverage new capital for growth, but high execution and regulatory risks warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
